Q-omics provides the consensus-scored MIR34AHG profile across patient tissues and cancer cell-line models. MIR34AHG expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, MIR34AHG is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, MIR34AHG RNA expression shows 17,427 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, THCA, and THYM as cancer lineages where MIR34AHG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR34AHG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR34AHG survival associations across molecular data types. MIR34AHG RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR34AHG RNA expression–survival associations across cancer types. High MIR34AHG expression shows unfavorable associations in LGG, but favorable associations in LUAD, HNSC, KIRP, UCEC and READ. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for MIR34AHG RNA expression.
This table summarizes MIR34AHG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR34AHG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR34AHG shows lower tumor expression in KICH and higher tumor expression in THCA, KIRC, COAD, BLCA and LIHC. The THCA box plot shows higher MIR34AHG RNA expression in tumor versus normal tissue (log2 FC = +0.734, t-test p < 0.001).
This table shows molecular features associated with MIR34AHG in patient tissues and cancer cell lines. In patient samples, MIR34AHG shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
